Luca Alberici (MolMed S.p.A. (MLMD.MI))

Alberici, Luca (Asahi Glass 202403 General Manager + Managing Director at AGC Biologics Italy before MolMed 201903 CBO)

	Organisation	MolMed S.p.A. (MLMD.MI)
	Group	Asahi Glass (AGC) (Group)
	Product	gene therapy
	Product 2	vector (biotech)

MolMed S.p.A.. (3/13/19). "Press Release: Partnership in the Field of Rare Genetic Diseases with Rocket Pharma Extended to Three New Therapeutic Indications". Milan.

MolMed S.p.A. ("MolMed", MLMD.MI), clinical stage biotechnology company focusing on research, development, manufacturing and clinical validation of cell & gene therapies for the treatment of cancer and rare diseases, announce to have renewed and extended to three new therapeutic indications the collaboration, launched in February 2017, with Rocket Pharmaceuticals Ltd. ("Rocket Pharma"), US company specialized in the development of innovative therapies for the treatment of rare genetic diseases.

With the renewal and extension of the development and manufacturing service agreement, initially related to a gene therapy product for the treatment of only Fanconi Anemia, Rocket Pharma will entrust MolMed with the activities related to the production of lentiviral vectors to be used in three new therapeutic indications.

Luca Alberici, MolMed's Chief Business Officer, commented: "We are pleased to have strengthened our collaboration with Rocket Pharma, a company that is emerging as an international leader in the field of cell & gene therapy, and to support them in their mission of bringing transformative therapies to patients suffering from severe rare diseases still without a cure".

Riccardo Palmisano, MolMed’s CEO added: “This new result, a few days after the renewal and extension of the agreement with Genenta, confirms the satisfaction of our customers and further strengthens the value and growth prospects of our GMP production for third parties”.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, is looking forward to obtain the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase; the product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the field of innovative oncological therapies MolMed pipeline also includes NGR-hTFN, a therapeutic agent for the treatment of solid tumors. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti
Investor Relations & Communication Manager
MolMed S.p.A.
+39 02 21277.205
+39 02 21277.325
investor.relations@molmed.com

Tommasina Cazzato
Press Office
Community Group
+39 345 7357751
tommasina.cazzato@communitygroup.it